Enzyme Engineering & Biocatalysis
·
Transaminase Biocatalysis Engineering
Transaminase Engineering
Does transaminase variant ranking on 2,2-dimethyl-1-phenyl-propan-1-one at 5 g/L hold when substrate loading is increased to 75 g/L?
THE QUESTION
Which transaminase variant aminates a named bulky ketone at conversion above [threshold] and ee above [threshold] at substrate loading above [threshold] g/L? Verifier: expressed panel with chiral HPLC. Note: PLP-cofactor-dependent modelling is absent from the corpus. [baseline: to verify]
WORK ORDER
Performance of a twelve-member transaminase panel on 2,2-dimethyl-1-phenyl-propan-1-one at 5 and 75 g/L
BACKGROUND
What this Apodex Lab is
Manufacturing chiral amines from sterically hindered ketones avoids transition metals and resolution steps when an amine transaminase enzyme performs the direct asymmetric amination. Operating these reactions at commercial scale requires enzymes that tolerate high substrate concentrations, often between 50 and 150 g/L, alongside organic co-solvents and molar donor concentrations. However, variant discovery and sequence engineering take place almost exclusively at screening loadings of 5 to 10 g/L. Route selection for manufacturing steps currently relies on low-concentration assays that have never been shown to predict enzyme behaviour at production scale.
The academic literature attributes poor transaminase activity on bulky ketones to steric constraint within the active site, publishing pocket-opened variants evaluated under dilute screening conditions. Industrial patent estates instead define variants by process robustness, including product inhibition, co-solvent stability, and operation at elevated substrate charge. Because foundational patents from 2009 and 2010 priority have reached the end of their term, industrially claimed sequences can now be benchmarked directly alongside academic variants. No printed dataset has tested whether the activity rankings established at 5 g/L reorder when challenged with 75 g/L nominal substrate in 30 per cent v/v DMSO, leaving unmeasured how much conversion loss stems from active-site fit versus process intolerance.
The Transaminase Engineering Apodex Lab resolves this gap by executing a twelve-member panel of mixed provenance on the benchmark bulky ketone 2,2-dimethyl-1-phenyl-propan-1-one. Expressed uniformly in Escherichia coli lysate and normalised by both soluble transaminase content and unit activity, each variant is evaluated at 5 and 75 g/L substrate loading with 0.5 M isopropylamine and 1 mM pyridoxal-5-phosphate at 30 °C. Qualified chiral chromatography delivers 24 h conversion, enantiomeric excess, catalyst productivity, and actual dissolved substrate loading to pre-set confidence intervals. The resulting rank correlation and productivity figures determine whether route developers can rely on sequence-based triage and dilute screening or must instead incorporate high-loading assays and enzyme recycle development directly into early evolution rounds.
WHY NOW
Why the field is spending on an assumption
Biocatalytic amination of bulky ketones is routinely evaluated at 5 to 10 g/L substrate loading. Routes to chiral amines are committed on these screening results, yet whether variant performance rankings transfer to industrial loadings of 50 to 150 g/L remains unmeasured. Two developments change this. Foundational patent claims from 2009 and 2010 priority have expired, allowing industrial transaminase sequences to be synthesised and benchmarked openly against academic variants without freedom-to-operate constraints. Simultaneously, sequence-activity landscape models now permit prospective ranking from public data. The field cannot presently determine how much high-loading conversion loss stems from active-site steric constraints rather than process factors such as product inhibition and solvent tolerance.
WHAT WE’D BUY
What we would ask a laboratory to run
We are not buying the answer. We are buying a measurement with an interval — and the bars it will be compared against.
A contract laboratory expresses a twelve-member omega-transaminase panel in Escherichia coli BL21(DE3) lysate, normalised by protein densitometry and activity units. The panel converts 2,2-dimethyl-1-phenyl-propan-1-one to its chiral amine with isopropylamine and pyridoxal-5-phosphate at 5 g/L and 75 g/L nominal loading. For each variant at 75 g/L, qualified chiral HPLC measures 24-hour conversion to within a 90 per cent confidence interval half-width of 4 percentage points, enantiomeric excess to within 1 percentage point, and catalyst productivity in grams of product per gram of soluble protein. The delivery includes actual dissolved substrate concentrations, four determinations per variant at 5 g/L, the measured conversion drop between loadings, and rank correlation against a sealed pre-registered prediction.
SCOPE & LIMITS
Because assays use fresh clarified lysate in sealed 1 mL vials without enzyme recycling or immobilisation, delivered productivity values represent an upper bound rather than operating plant performance.
WHO EXECUTES
The kind of lab that can run this
A biocatalysis contract research organisation with protein expression capacity (E. coli shake-flask to 1 L fermenter), PLP-dependent enzyme assay experience, and chiral HPLC/GC analytics on site.
EXECUTOR KIND
wet-lab
WAYS IN
FOR PIs, LABS & CROs
Complete tasks no model can.
Paid per task, credited by name — a “Verified by” line for as long as the discovery it settled exists. You choose the work: browse the tasks above, respond to what you can actually run.
CREATE AN APODEX LAB
Have a question of your own?
Give it its own laboratory. Watch it decompose into an executable manifest.
ASK A FOLLOW-UP QUESTION
Push on our assumptions.
Every Apodex Lab lists what it doesn’t know. Good questions compound.
Every Apodex Lab shares the same verified-knowledge ledger. No laboratory works alone.